Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4

Cancer Research

Volumn 56, Issue 8, 1996, Pages 1828-1833

  Wakimoto, Hiroaki ^a,b   Abe, Junko ^a   Tsunoda, Rikiya ^c   Aoyagi, Masaru ^b   Hirakawa, Kimiyoshi ^b   Hamada, Hirofumi ^a  

^a CANCER INSTITUTE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; GANGLIOTETRAOSYLCERAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; DENDRITIC CELL; FEMALE; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IMMUNOPOTENTIATION; INFLAMMATORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

3T3 CELLS; ANIMALS; BRAIN NEOPLASMS; CYTOKINES; FEMALE; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-4; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RETROVIRIDAE; VACCINES, SYNTHETIC;

EID: 0029961016     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Fearon, E R , Pardoll, D M , Itaya, T , Golumbek, P , Levitsky, H I., Simons, J. W., Karasuyama, H , Vogelstein B , and Frost, P Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell, 60: 397-103, 1990.
2. Gansbacher, B , Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity J. Exp. Med., 172 1217-1224, 1990.
3. Tepper R I, Pattengale, P K., and Leder, P. Murine interleukin-4 displays potent anti-tumor activity in vivo Cell, 57. 503-512, 1989
4. Golumbek, P T., Lazenby, A J , Levitsky, H I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC), 254. 713-716, 1991.
5. Porgador, A , Tzehoval, E , Katz, A., Vadai, E. Revel, M , Feldman, M., and Eisenbach, L Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells Cancer Res., 52: 3679-3686, 1992.
6. Aoki, T., Tashiro, K., Miyatake, S., Kinashi, T., Nakano, T., Oda, Y., Kikuchi, H., and Honjo, T. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl. Acad. Sci USA, 89: 3850-3854, 1992.
7. Gansbacher, B , Bannerji, R., Daniels, B , Zier, K., Cronin, K., and Gilboa, E Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res , 50: 7820-7825, 1990.
8. Porgador, A , Bannerji, R , Watanabe, Y., Feldman, M. Gilboa, E , and Eisenbach, L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J. Immunol., 150: 1458-1470, 1993
9. Asher, A L., Mulé, J. J., Kasid, A., Restifo, N. P., Solo, J. C., Reichert, C. M., Jaffe, G., Fendly, B , Kriegler, M., and Rosenberg, S. A Murine tumor cells transduced with the gene for tumor necrosis factor-α. J. Immunol., 146: 3227-3234, 1991.
10. Chen, L., Ashe, S., Brady, W. A., Hellström, I , Hellström, K E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
11. + T cells by B7-transfected melanoma cells. Science (Washington DC), 259: 368-370, 1993
12. Townsend, S. E , Su, F. W., Atherton, J. M., and Allison, J. P. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res., 54: 6477-6483, 1994.
13. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P , Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci USA, 90: 3539-3543, 1993.
14. Sanda, M., G. Ayyagari, S R , Jaffee, E. M., Epstein, J I , Clift, S. L., Cohen, L. K., Dranoff, G., Pardoll, D. M., Mulligan, R. C., and Simons, J W Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol., 151: 622-628, 1994.
15. Allione, A., Consalvo, M , Nanni, P , Lollini, P. L., Cavallo, F., Giovarelli, M., Forni, M., Gulino, A. Colombo, M. P , Dellabona, P., Hock, H., Blankenstein, T. Rosenthal, F. M , Gansbacher, B , Bosco, M. C., Musso, T., Gusella, L , and Forni, G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin(IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res., 54: 6022-6026, 1994.
16. Connor, J., Bannerji, R., Saito, S , Heston, W , Fair, W , and Gilboa, E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells J. Exp. Med., 177: 1127-1134, 1993.
17. Vieweg, J., Rosenthal, F M , Bannerji, R., Heston, W. D. W , Fair, W. R., Gansbacher, B., and Gilboa, E. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res., 54, 1760-1765, 1994.
18. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice J Exp Med., 181: 619-629, 1995.
19. Saito, S., Bannerji, R., Gansbacher, B., Rosenthal, F. M., Romanenko, P , Heston, W. D. W., Fair, W. R., and Gilboa, E. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res., 54: 3516-3520, 1994.
20. Pardoll, D. M. Cancer vaccines. Immunol. Today, 14: 310-316, 1993.
21. Colombo, M. P., and Forni, G. Cytokine gene transfer in tumor inhibition and tumor therapy, where are we now? Immunol. Today, 15: 48-51, 1994.
22. Tepper, R. I., and Mule, J. J. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther., 5: 153-164, 1994.
23. Wakimoto, H., Abe, J., Nakamura, Y., Kanegae, Y., Saito, I. Aoyagi, M., Hirakawa, K., and Hamada, H. Enhanced antitumor effects by cytokine gene-modified tumor vaccines and IL-2-secreting cytotoxic T lymphocytes. In: T. Friedmann, Y. W. Kan, and R. Mulligan (eds.), Gene Therapy, p 164 Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1994
24. Abe, J , Wakimoto, H., Nakamura, Y., Kanegae, Y., Saito, I., Aoyagi, M., Hirakawa, K , and Hamada. H Immunogene therapy for cancer by cytokine gene-modified tumor vaccine and tumor-infiltrating lymphocytes (TIL). Cancer Gene Ther., 1, 312, 1994
25. Abe, J , Wakimoto, H., Nakamura, Y., Aoyagi, M., Hirakawa, K., and Hamada, H Cytokine gene-modified tumor vaccination intensified by a streptococcal preparation OK-432. Cancer Immunol. Immunother, 41: 82-86, 1995.
26. Abe, J , Wakimoto, H., Yoshida, Y , Aoyagi, M., Hirakawa, K., and Hamada, H. Antitumor effect induced by GM-CSF gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus-mediated genetic transduction J. Cancer Res. Clin. Oncol., 121: 587-592, 1995
27. Hanada, K., Wakimoto, H., Abe, J., Orimoto, K., Nakamura, Y., Murata, M , Hayashi, M., and Hamada, H. Strategies for immunogene therapy against cancer. In: K. Kimura, K Ota, S. K. Carter, and T. Friedmann (eds.), Cancer Chemotherapy Challenges for the Future, VI. 9, pp. 73-80 Tokyo: Excerpta Medica, 1994.
28. Hamada. H Tumor vaccines expressing cytokine genes: combination with adoptive immunogene therapy for cancer. Proc. Hiroshima Cancer Semin , 4: 17-20, 1994.
29. Danos, O , and Mulligan, R. C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA, 85, 6460-6464, 1988.
30. Fidler, I J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res., 35: 218-224, 1975.
31. Kruisbeek, A M In vivo depletion of CD4- and CD8-specific T cells. In. J. E Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (eds.), Current Protocols in Immunology, pp. 4.1 1-4.1.5. New York: Jon Wiley & Sons, 1994.
32. Goding, J. W. Monoclonal Antibodies Principles and Practice. London: Academic Press, 1983
33. Nakamura, Y., Wakimoto, H., Abe, J., Kanegae, Y., Saito, I., Aoyagi, M., Hirakawa, K., and Hamada, H. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin-2. Cancer Res., 54: 5757-5760, 1994
34. Pope, B L., Chourmouzis, E., Sigindere, J., MacIntyre, J. P , Capetola, R. J , and Lau, C. Y. In vivo activation of natural killer cells and priming of EL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine). Cell Immunol., 147: 302-312, 1993.
35. Fujii, Y., Sendo, F., Kamiyama, T., and Naiki, M IgG antibodies to asialoGM1 are more sensitive than IgM antibodies to kill in vivo natural killer cells and prematured cytotoxic T lymphocytes. Microbiol. Immunol , 34: 533-542, 1990.
36. Witmer-Pack, M D., Olivier, W., Valinsky, J., Schuler, G., and Steinman, R. M Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells J. Exp. Med., 166: 1484-1498, 1987.
37. Inaba, K., Steinman, R. M., Pack, M W , Aya, H , Inaba, M., Sudo, T., Wolpe, S., and Schuler, G Identification of proliferating dendritic cell precursors in mouse blood J. Exp Med., 175, 1157-1167, 1992
38. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.
39. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J. Exp. Med . 179: 1109-1118, 1994
40. + derived dendritic/Laagerhans cells (DLC). In. S. Banchereau and D. Schmitt (eds.), Dendritic Cells in Fundamental and Clinical Immunology. VI. 2, pp. 1-5 New York: Plenum Press, 1995.
41. Wekerle, H. Lymphocyte traffic to the brain. In: W. M. Pardridge (ed.), The Blood-Brain Barrier, pp. 67-85. New York: Raven Press, 1993.
42. Kuppner, M. C., Hamou, M F., and de Tribolet, N. Immunohistological and functional analyses of lymphoid infiltrates in human glioblastoma. Cancer Res., 48, 6926-6932, 1988.
43. Cserr, H. F , and Knopf, P. M. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new review. Immunol. Today, 13: 507-512, 1992
44. Denlinger, R. H., Axler, D. A., Koestner, A., and Liss, L. Tumor-specific transplantation immunity to intracerebral challenge with cells from a methylnitrosourea-induced brain tumor. J. Med. (Westbury), 6: 249-259, 1975.
45. Abe, J , Wakimoto, H., Tsunoda, R., Okabe, S., Yoshida, Y., Aoyagi, M , Hirakawa, K., and Hanada, H In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-α by adenovirus-mediated genetic transduction. Biochem. Biophys Res. Commun., 218: 164-170, 1996.
46. Berns, A J. M., Clift, S., Cohen, L K., Donehower, R C., Dranoff, G., Handa, K. M., Jaffee, E. M., Lazenby, A. J , Levitsky, H I., Marshall, F F., Mulligan, R. C., Nelson, W. G., Owens, Jr., A. H., Pardoll, D. M., Parry, G., Partin, A H., Piantadosi, S , Simons, J. W., and Zabora, J. R. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther., 6: 347-368, 1995.
47. Shinnick, T M., Lerner, R A , and Sutcliffe, J. G. Nucleotide sequence of Moloney murine leukemia virus Nature (Lond.), 293: 543-548, 1981.